1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium | Zendy

Glen P. Carter | Zendy; Jitendra R. Harjani | Zendy; Lucy Z. Li | Zendy; Noel P. Pitcher | Zendy; Yi g | Zendy; Thomas V. Riley | Zendy; Deborah A. Williamson | Zendy; Timothy P. Stinear | Zendy; Jonathan B. Baell | Zendy; Benjamin P. Howden | Zendy

Open Access

1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium

Author(s) -

Glen P. Carter,

Jitendra R. Harjani,

Lucy Z. Li,

Noel P. Pitcher,

Yi g,

Thomas V. Riley,

Deborah A. Williamson,

Timothy P. Stinear,

Jonathan B. Baell,

Benjamin P. Howden

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky064

Subject(s) - daptomycin , enterococcus faecium , microbiology and biotechnology , enterococcus , antimicrobial , medicine , chemistry , antibiotics , biology , staphylococcus aureus , bacteria , vancomycin , genetics

Enterococcus faecium is an important nosocomial pathogen. It has a high propensity for horizontal gene transfer, which has resulted in the emergence of MDR strains that are difficult to treat. The most notorious of these, vancomycin-resistant E. faecium, are usually treated with linezolid or daptomycin. Resistance has, however, been reported, meaning that new therapeutics are urgently needed. The 1,2,4-oxadiazoles are a recently discovered family of antimicrobials that are active against Gram-positive pathogens and therefore have therapeutic potential for treating E. faecium. However, only limited data are available on the activity of these antimicrobials against E. faecium.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research